Goldman says this biotech stock will be a winner thanks to a one-of-a-king treatment
- Posted on May 26, 2026
- By CNBC
- 0 Views
- 1 min read
Goldman says this biotech stock will be a winner thanks to a one-of-a-king treatment
Hemab Therapeutics is likely to gain ground as its treatment for a pair of rare bleeding disorders shows signs of efficacy, per Goldman Sachs.
